Tysabri/JCV Antibodies

This case study shows how taking a proactive approach to risk stratification by means of a diagnostic test, even in the case of severe adverse events, can help rescue and reposition an otherwise highly effective drug. Using Tysabri as an example, the case study also shows that the diagnostic lifecycle can evolve depending on the changing testing requirements for a drug. It will help you understand:
  • That a rare but serious adverse event, only discovered after the approval of natalizumab (Tysabri), changed the commercial trajectory for this highly promising novel multiple sclerosis therapy
  • How Biogen Idec and Elan took a very proactive approach to identifying the key risk factor for this serious adverse event and to developing a commercially available risk test, aided by strategic diagnostic partners
  • How the development and launch of the novel JC virus (JCV) diagnostic test was set to help reposition Tysabri, gain market share and recover lost Tysabri value
  • How the diagnostic lifecycle may evolve depending on a change in testing  and any adjustments a drugowner has to make
Download this case study to learn more.
Existing Users Log In